The animal vaccines market is broadly segmented into two key categories: livestock and companion animals. In 2024, the livestock category dominated the market with a valuation of USD 6.4 billion. Livestock species such as poultry, cattle, swine, and aquaculture are critical to global food security and agricultural economies. Preventing disease outbreaks in these animals is crucial to maintaining productivity and minimizing financial losses. Incidences of foot-and-mouth disease, swine fever, and avian influenza remain serious concerns in this sector, reinforcing the need for robust vaccination strategies. While the companion animal segment is also expanding due to rising pet ownership and increased attention to pet wellness, the livestock segment continues to generate the highest revenue.
Vaccines in the animal health sector include several types, such as attenuated live, conjugate, inactivated, DNA, recombinant, and others. Among these, attenuated live vaccines held the highest market share in 2024, accounting for 44.1% of the total. These vaccines are widely favored for their ability to produce strong immune responses and deliver long-term protection. Their capability to stimulate both humoral and cell-mediated immunity often reduces the need for repeated doses, making them a preferred option in both livestock and companion animal vaccination programs.
North America accounted for 40.6% of the global animal vaccines market in 2024. This dominant share is driven by a large population of domesticated animals and livestock in the region. The United States leads in pet ownership and has a well-established agricultural sector comprising cattle, poultry, and swine. The ongoing focus on maintaining herd health and minimizing infectious disease risks continues to drive vaccine adoption in the region.
Key players shaping the global animal vaccine landscape include Zoetis, Merck Animal Health, Virbac, Boehringer Ingelheim International, Bioveta, Brilliant Bio Pharma, Dechra Pharmaceuticals, Vetoquinol, Neogen Corporation, Elanco Animal Health, Hipra Animal Health Limited, and Henry Schein Animal Health (Covetrus, Inc.). These companies are actively expanding their vaccine portfolios through extensive research and development. Strategic partnerships with veterinary organizations and government agencies are helping improve vaccine accessibility. Additionally, the adoption of advanced technologies like genetic engineering and recombinant DNA is enabling the creation of more effective, long-lasting vaccines tailored to evolving disease threats.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Companies Mentioned
The companies featured in this Animal Vaccines market report include:- Boehringer Ingelheim International
- Brilliant Bio Pharma
- Bioveta
- Ceva Sante Animale
- Durvet
- Dechra Pharmaceuticals
- Elanco Animal Health
- Henry Schein Animal Health (Covetrus, Inc.)
- Hipra Animal Health Limited
- Indian Immunologicals
- Merck Animal Health
- Neogen Corporation
- Vetoquinol
- Virbac
- Zoetis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 132 |
| Published | April 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 9.9 Billion |
| Forecasted Market Value ( USD | $ 19 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |


